Lipocine announces financial results for the year ended december 31, 2020

Salt lake city, march 11, 2021 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the fourth quarter and year ended december 31, 2020, and provided a corporate update. "lipocine had a number of important accomplishments in 2020, most notably the u.s. food and drug administration ("fda") decision to grant tentative approval to tlando, the company's oral testosterone product for testosterone replacement therapy ("trt") in adult males with hypogonadism.
LPCN Ratings Summary
LPCN Quant Ranking